Navigation Links
Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
Date:7/15/2008

ATHENS, Ga., July 15 /PRNewswire/ -- Abeome Corporation, a Georgia-based biotech company, announced today a strategic equity investment by Cato BioVentures and a collaboration with Cato Research Ltd., its global contract research and development organization. The investment and collaboration will help support continued development of Abeome's lead ovarian cancer project.

Abeome's proprietary technology vastly improves the development of monoclonal antibodies and Abeome is deploying its technology to provide a shotgun approach to develop an array of antibodies for an ovarian cancer therapeutic target. The company has developed novel monoclonal antibodies to four ovarian cancer cell lines and has begun screening these antibodies in search of those which cause either cancer cell growth inhibition or death.

Joel Eisner, Ph.D., Associate Principal of Cato BioVentures, states, "We are fascinated with Abeome's ability to develop such a large library of monoclonal antibodies by use of their technology. They have pushed the bottleneck of therapeutic development to the screening step which will provide a broader selection of novel antibodies to more cancer targets."

Monoclonal antibodies have become the centerpiece of many high-profile therapeutic products. Their specificity to disease targets, like cancer, has drawn significant attention from the biotech community.

"Ovarian cancer is a dreadful disease which is frequently diagnosed at a very late stage of development. With no effective therapeutic drugs on the market to date, we expect to address this unmet medical need. Our technology improves the likelihood of finding that one-of-a-kind antibody that can make the difference," said Mike Wanner, President and CEO of Abeome. "We are excited to have Cato Research join our expanding team of professional experts to help us with this important project".

About Abeome

Abeome Corporation is a biotechnology company dedicated to leveraging its proprietary hybridoma technology to accelerate and improve the development of monoclonal antibodies for life sciences. Abeome owns an exclusive license for the technology from the University of Georgia Research Foundation and has garnered significant support from the Georgia Research Alliance.

For more information on Abeome, visit http://www.abeomecorp.com .

About Cato BioVentures

Cato BioVentures is the venture capital affiliate of Cato Research Ltd. and has assisted entrepreneurs and established management teams in building successful life science companies. Through strategic CRO service agreements with Cato Research, Cato BioVentures invests its in-kind CRO Service Capital(TM) in innovative therapeutics, medical devices, diagnostics and platform technologies for improved drug discovery and development, offering promising life science companies immediate access to a broad range of essential CRO services on a noncash basis. Access to these time-critical CRO services enables management to achieve key value-added development and regulatory milestones with less reliance on other sources of capital. Cato BioVentures has offices in Boston's Bay Colony, Research Triangle Park and Silicon Valley.

For more information on Cato BioVentures, visit http://www.catobioventures.com .


'/>"/>
SOURCE Abeome Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Snapshots of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report
2. Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect
3. Secretary Reinforces VAs Commitment to Research Safety and Veteran Focus
4. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Pediatric Researchers Find Possible Master Switch Gene in Juvenile Arthritis
7. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
8. Small Business Innovation Research Program Awards Grant to Biomoda
9. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
10. New Research Just Released: Women Can Now Safely Postpone Motherhood Until Time Is Right
11. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... and other leading institutions in announcing the launch of the Leadership Circle ... way animals are raised for food. , Founding members of the Leadership Circle ...
Breaking Medicine News(10 mins):